Skip to main content
Top
Published in: Acta Diabetologica 3/2009

01-09-2009 | Original Article

Glomerular hyperfiltration and metabolic syndrome: results from the FIrenze-BAgno A Ripoli (FIBAR) Study

Authors: Matteo Monami, Laura Pala, Gianluca Bardini, Paolo Francesconi, Barbara Cresci, Niccolò Marchionni, Carlo Maria Rotella, Edoardo Mannucci

Published in: Acta Diabetologica | Issue 3/2009

Login to get access

Abstract

Metabolic syndrome (MS) has been associated with microalbuminuria and kidney disease. In the present cohort study, different methods for the estimation of glomerular filtration rate (GFR) on the basis of serum creatinine were compared with respect to their association with MS and their predictive value for incident diabetes mellitus. The present analysis was performed on the cohort of subjects enrolled in the FIBAR study, a screening program for diabetes. GFR was estimated (eGFR) using three different methods: Cockroft-Gault (CG) formula, using actual body weight (CAW), CG formula using ideal body weight (CIW), and Modification of Diet in Renal Disease formula (M). The study was performed on 2,694 nondiabetic subjects, without history of renal insufficiencey or serum creatinine at baseline >1.5 mg/dl. Mean follow-up was 27.8 ± 11.5 months. Elevated eGFR, estimated with different methods, was associated with increased prevalence of most components of MS; however, an association between elevated clearance and MS was observed only when using CAW, which overestimates filtration in obese subjects. During follow-up, 40 new cases of diabetes were recorded (0.5/100 patient*years). After adjusting for age and sex, the HR (with 95% confidence intervals) for diabetes for patients in the highest quintile of eGFR was 1.14 [0.44–2.99], 0.89 [0.31–2.51], and 1.01 [0.42–2.41] for formula CAW, CIW, and M, respectively (all p > 0.7). Elevated eGFR, estimated through methods which do not produce a systematic overestimate in obese subjects, is not associated with the diagnosis of MS, and does not predict diabetes.
Literature
1.
go back to reference Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183–1197 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183–1197
2.
go back to reference Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497
3.
go back to reference Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedCrossRef Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedCrossRef
5.
go back to reference Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
6.
go back to reference Chien KL, Hsu HC, Lee YT, Chen MF (2008) Renal function and metabolic syndrome components on cardiovascular and all-cause mortality. Atherosclerosis 197:860–867PubMedCrossRef Chien KL, Hsu HC, Lee YT, Chen MF (2008) Renal function and metabolic syndrome components on cardiovascular and all-cause mortality. Atherosclerosis 197:860–867PubMedCrossRef
7.
go back to reference De Cosmo S, Trevisan R, Minenna A, Vedovato M, Viti R, Santini SA, Dodesini AR, Fioretto P, Trischitta V (2006) Insulin resistance and the cluster of abnormalities related to the metabolic syndrome are associated with reduced glomerular filtration rate in patients with type 2 diabetes. Diabetes Care 29:432–434PubMedCrossRef De Cosmo S, Trevisan R, Minenna A, Vedovato M, Viti R, Santini SA, Dodesini AR, Fioretto P, Trischitta V (2006) Insulin resistance and the cluster of abnormalities related to the metabolic syndrome are associated with reduced glomerular filtration rate in patients with type 2 diabetes. Diabetes Care 29:432–434PubMedCrossRef
8.
go back to reference Tomaszewski M, Charchar FJ, Maric C et al (2007) Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int 71:816–821PubMedCrossRef Tomaszewski M, Charchar FJ, Maric C et al (2007) Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int 71:816–821PubMedCrossRef
9.
go back to reference Mannucci E, Ognibene A, Sposato I et al (2003) Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 40:181–186PubMedCrossRef Mannucci E, Ognibene A, Sposato I et al (2003) Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 40:181–186PubMedCrossRef
10.
go back to reference Obesity: preventing and managing the global epidemic (2000) Report of a WHO consultation. World Health Organ Tech Rep Ser 894:i–253 Obesity: preventing and managing the global epidemic (2000) Report of a WHO consultation. World Health Organ Tech Rep Ser 894:i–253
11.
go back to reference Chalmers J, MacMahon S, Mancia G et al (1999) 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 21:1009–1060PubMedCrossRef Chalmers J, MacMahon S, Mancia G et al (1999) 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 21:1009–1060PubMedCrossRef
12.
go back to reference Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
13.
go back to reference Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–470PubMed Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–470PubMed
14.
go back to reference Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289–2304PubMedCrossRef Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289–2304PubMedCrossRef
16.
go back to reference Valensi P, Assayag M, Busby M, Paries J, Lormeau B, Attali JR (1996) Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 20:574–579PubMed Valensi P, Assayag M, Busby M, Paries J, Lormeau B, Attali JR (1996) Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 20:574–579PubMed
17.
go back to reference Rutkowski P, Klassen A, Sebekova K, Bahner U, Heidland A (2006) Renal disease in obesity: the need for greater attention. J Ren Nutr 16:216–223PubMedCrossRef Rutkowski P, Klassen A, Sebekova K, Bahner U, Heidland A (2006) Renal disease in obesity: the need for greater attention. J Ren Nutr 16:216–223PubMedCrossRef
18.
go back to reference Knight SF, Imig JD (2007) Obesity, insulin resistance, and renal function. Microcirculation 14:349–362PubMedCrossRef Knight SF, Imig JD (2007) Obesity, insulin resistance, and renal function. Microcirculation 14:349–362PubMedCrossRef
19.
go back to reference Sarafidis PA, Ruilope LM (2006) Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 26:232–244PubMedCrossRef Sarafidis PA, Ruilope LM (2006) Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 26:232–244PubMedCrossRef
20.
go back to reference Chalmers L, Kaskel FJ, Bamgbola O (2006) The role of obesity and its bioclinical correlates in the progression of chronic kidney disease. Adv Chronic Kidney Dis 13:352–364PubMedCrossRef Chalmers L, Kaskel FJ, Bamgbola O (2006) The role of obesity and its bioclinical correlates in the progression of chronic kidney disease. Adv Chronic Kidney Dis 13:352–364PubMedCrossRef
21.
go back to reference Bosma RJ, Kwakernaak AJ, van der Heide JJ, de Jong PE, Navis GJ (2007) Body mass index and glomerular hyperfiltration in renal transplant recipients: cross-sectional analysis and long-term impact. Am J Transplant 7:645–652PubMedCrossRef Bosma RJ, Kwakernaak AJ, van der Heide JJ, de Jong PE, Navis GJ (2007) Body mass index and glomerular hyperfiltration in renal transplant recipients: cross-sectional analysis and long-term impact. Am J Transplant 7:645–652PubMedCrossRef
22.
go back to reference Bosma RJ, Krikken JA, van der Homan Heide JJ, de Jong PE, Navis GJ (2006) Obesity and renal hemodynamics. Contrib Nephrol 151:184–202PubMedCrossRef Bosma RJ, Krikken JA, van der Homan Heide JJ, de Jong PE, Navis GJ (2006) Obesity and renal hemodynamics. Contrib Nephrol 151:184–202PubMedCrossRef
24.
go back to reference Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y (2003) The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14:1480–1486PubMedCrossRef Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y (2003) The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14:1480–1486PubMedCrossRef
25.
go back to reference Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716PubMedCrossRef Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716PubMedCrossRef
26.
go back to reference Bruno G, Merletti F, Biggeri A et al (2004) Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27:2689–2694PubMedCrossRef Bruno G, Merletti F, Biggeri A et al (2004) Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27:2689–2694PubMedCrossRef
27.
go back to reference Mannucci E, Monami M, Cresci B et al (2007) National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study. Diabetes Obes Metab 10(5):430–435PubMedCrossRef Mannucci E, Monami M, Cresci B et al (2007) National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study. Diabetes Obes Metab 10(5):430–435PubMedCrossRef
Metadata
Title
Glomerular hyperfiltration and metabolic syndrome: results from the FIrenze-BAgno A Ripoli (FIBAR) Study
Authors
Matteo Monami
Laura Pala
Gianluca Bardini
Paolo Francesconi
Barbara Cresci
Niccolò Marchionni
Carlo Maria Rotella
Edoardo Mannucci
Publication date
01-09-2009
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2009
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-008-0074-3

Other articles of this Issue 3/2009

Acta Diabetologica 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.